Progression of Kidney Disease in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin Versus Usual Care: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Randomization and follow-up of participants with a valid baseline estimated glomerular filtration rate (eGFR) in the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Statin use and lipid levels during the course of the study. Abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein. To convert total, LDL, and HDL cholesterol in mg/dL to mmol/L, multiply by 0.02586; triglycerides in mg/dL to mmol/L, multiply by 0.01129.

Survival curves for kidney disease events; pravastatin versus usual care. Treatment groups by baseline estimated glomerular filtration rate (eGFR) estimates: (A-C) all participants (n = 10,060), and (D-F) the subgroup of participants with baseline GFR less than 60 mL/min/1.73 m² (n = 1,557). Abbreviation: ESRD, end-stage renal disease. To convert GFR in mL/min/1.73 m² to mL/s/1.73 m², multiply by 0.01667.

Renal outcomes in the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial by treatment group and glomerular filtration rate (GFR) group at baseline (relative risks and 95% confidence intervals, 6-year rates per 100, and total events). Abbreviation: ESRD, end-stage renal disease. To convert GFR in mL/min/1.73 m² to mL/s/1.73 m², multiply by 0.01667.

Estimated glomerular filtration rate (eGFR; mL/min/1.73 m²) during the course of the study. To convert GFR in mL/min/1.73 m² to mL/s/1.73 m², multiply by 0.01667.